TABLE 3.
Summary of multivariate analysis for os and pfs in patients with ESCC
| Prognostic factor | OS | P | PFS | P | ||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Age(＜60 vs ≥ 60) | 0.994 | 0.712‐1.387 | .970 | 0.900 | 0.679‐1.193 | .464 |
| Gender (Male vs Female) | 0.945 | 0.606‐1.474 | .805 | 1.084 | 0.754‐1.560 | .663 |
| Tumor location (baseline, Upper) | .012 | .003 | ||||
| Middle | 1.244 | 0.868‐1.785 | .235 | 1.453 | 1.073‐1.966 | .016 |
| Lower | 1.936 | 1.251‐2.997 | .003 | 1.891 | 1.266‐2.824 | .002 |
| T category (baseline, T2) | .011 | .004 | ||||
| T3 | 1.370 | 0.841‐2.231 | .206 | 1.420 | 0.960‐2.101 | .079 |
| T4 | 2.160 | 1.246‐3.744 | .006 | 2.115 | 1.338‐3.342 | .001 |
| N category (N0, N1 vs N2, N3) | 1.692 | 1.219‐2.348 | .002 | 1.477 | 1.108‐1.970 | .008 |
| Clinical response (good vs poor) | 1.806 | 1.305‐2.500 | .000 | 1.387 | 1.078‐1.697 | .043 |
OS, overall survival; ESCC, esophageal squamous cell carcinoma; HR, hazards ratio; CI, confidence interval; PFS, progression‐free survival.